

March 18, 2022

From Eric's Desk

Many of us spent the past week—actually, the past several weeks—getting ready for our annual visit from Yale Cancer Center's External Scientific Advisory Board. The event lasted all day, and colleagues from around the country listened to presentations from our leadership and provided detailed commentary about our program. Most importantly, they wanted to understand how we interact with one another and with others around the world when it comes to cancer research.

I would be dishonest if I did not acknowledge my own anxiety leading up to the day. Like many of us, I was convinced that our reviewers and my colleagues would feel that I was just a shameless imposter, totally incapable of tackling the job at hand. I survived those initial butterflies, and the day proceeded without any major obstacles. I quickly realized how much work is ahead of us before we submit our Cancer Center Support Grant application in September 2023. But more than any other take-home message, I was left with deep respect and admiration for my colleagues at Yale who presented to the panel, as well as those who were supporting us in many capacities behind the scenes.

It is all too easy to take what one has for granted. We are often reminded that we should not take anything for granted, but still, many of us easily lapse into this very familiar approach. For me, yesterday showed me how much raw talent, boundless energy, and limitless potential are part of the fabric of our Cancer Center. This weekend, I will wear my newly purchased blue fleece vest with the big white "Y" on the left upper chest a little more proudly.

Eric

Announcements

U01 Grant Awarded to Support TEAL Trial

The National Cancer Institute recently awarded Yale Cancer Center and the Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer. Melinda Irwin, PhD, MPH, the Susan Dwight Bliss Professor of Epidemiology and Associate Dean of Research at the Yale School of Public Health, and Associate Director (Population Sciences) at Yale Cancer Center

will lead the research project, "Trial of Exercise and Lifestyle (TEAL) in


from the desk of
Eric P. Winer, MD
Director, Yale Cancer Center
Physician-in-Chief,
Smilow Cancer Hospital

Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center

Yale Scientists Discover a New
Pathogenic Mechanism in Hematological
Malignancies



Women with Ovarian Cancer. The grant funding will enable Dr. Irwin and colleagues to investigate ways to improve treatment outcomes via diet and exercise in women newly diagnosed with ovarian cancer.

The study will enroll 200 women newly diagnosed with ovarian cancer and conduct a multi-site randomized trial over 18 weeks. The research team's hypothesis is that exercise and eating a healthy diet will improve chemotherapy toxicity and treatment adherence and efficacy, and in turn, improve ovarian cancer prognosis. Dietitians Maura Harrigan, MS, RDN, CSO and Courtney McGowan, RD, will be critical in helping with the diet intervention, and Linda Gottlieb, MA, CPT, CET, will assist with the exercise intervention.

[Learn More](#)

Call for Closer to Free Volunteers!

If you are interested in volunteering to support our Closer to Free ride this year, please complete the [CTF Volunteer Registration](#) and join our Yale Cancer Center Administration Team!

When registering, you will have the opportunity to select your top 3 shift preferences—you can find more details about the various volunteer role descriptions [here](#). When the time comes to assign the specific volunteer shift/roles, the CTF planning team will work with us to coordinate assignments. Together, we will also set a team fundraising goal that our individual fundraising efforts can help to collectively achieve. For more information on volunteering with the YCC Administration Team, please contact [Anna Raso](#).

Notables


Prajwal Boddu, MD, a fourth year fellow in Hematology/Oncology and graduate student in the Investigative Medicine Program, was awarded a 3-year Young Investigator Award from **EvansMDS**, the primary funding initiative of the **Edward P. Evans Foundation**, dedicated to research in Myelodysplastic Syndromes (MDS). Dr. Boddu's project entitled, "Mechanisms of Altered RNA Fate and Processing in MDS-associated Mutations in Splicing Factors," will be conducted under the mentorship of Manoj M. Pillai, MBBS, Associate Professor of Medicine (Hematology) and Pathology, with additional guidance from Karla Neugebauer, PhD, Professor of Molecular Biophysics and Biochemistry and of Cell Biology, and Markus Müschen, MD, PhD, Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology, and Director of the Center of Molecular and Cellular Oncology.

Anup Sharma, MD, PhD, Research Scientist in the laboratory of **Nita Ahuja, MD, MBA, FACS**, William H. Carmalt Professor of Surgery and Chair of Surgery, is the recipient of a \$50,000 grant from the **Ron Foley Foundation, Inc.** to advance his research on the epigenetic basis of racial disparity in pancreas cancer. Dr. Sharma will use the funding to research the development of new, targeted therapies for historically marginalized patients.

Mathieu Bakhom, MD, PhD, Assistant Professor of Ophthalmology and Pathology and a member of Yale Cancer Center's Genomics, Genetics, and


[Read More](#)

New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer



[Read More](#)

Yale Cancer Center Scientists 'Supercharge' Cancer-Fighting T Cells



[Read More](#)

JCO Consultant Editor for Meeting Abstracts Dr. Pamela Kunz Exploring Innovative Ways to Amplify Diverse Voices



[Read More](#)

Michael Hurwitz, PhD, MD, Shares Why He's a Kidney Cancer Physician/Scientist



Epigenetics Research Program, has been named one of the 12 members of the **NCI Early-Stage Surgeon Scientist Program** for 2022. The program is designed to train surgeon scientists and retain them in cancer research by supporting a program focused on cancer-related disease and basic and translational research.

Kim Blenman, PhD, MS, Assistant Professor of Medicine (Medical Oncology) and Assistant Professor of Computer Science, chaired a session at the **Melanoma Research Alliance Scientific Retreat** last week on “Highlighting MRA Young Investigator Awardees.”

The Mark Foundation for Cancer Research has selected four scientific research projects to receive \$12 million in funding for its **2022 Endeavor Awards**. **Nikhil Joshi, PhD**, Assistant Professor of Immunobiology, and **Aaron Ring, MD, PhD**, Assistant Professor of Immunobiology, both members of Yale Cancer Center’s Cancer Immunology Research Program, are part of a five person team funded to study, “Harnessing Tertiary Lymphoid Structure Function for Improved Immunotherapeutic Strategies in Cancer Patients.”

Valentina Greco, PhD, Carolyn Walch Slayman Professor of Genetics and a member of Yale Cancer Center’s Cancer Signaling Networks Research Program, has been elected vice president of the **International Society for Stem Cell Research** (ISSCR). After two years in that position, Dr. Greco will begin a one-year term as ISSCR’s president in July 2024. During Dr. Greco’s first year as vice president, beginning July 2022, **Haifan Lin, PhD**, Eugene Higgins Professor of Cell Biology and Professor of Genetics and of Obstetrics, Gynecology, & Reproductive Sciences, Director of Yale Stem Cell Center, and member of Yale Cancer Center’s Genomics, Genetics, and Epigenetics Research Program, will serve his term as ISSCR president.

Prasanna Ananth, MD, MPH, Assistant Professor of Pediatrics (Hematology/Oncology) and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, presented an oral abstract on “*From Concept to Care: Stakeholder Engaged Research*”: *Parent Priorities in End-of-Life Care for Children with Cancer* at the **2022 State of the Science in Hospice and Palliative Care**, held virtually February 12-13 and supported by the **American Academy of Hospice and Palliative Medicine** and **Hospice and Palliative Nurses Association**.

Walton (Skip) Heley III presented **Ian Krop, MD, PhD**, Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research, and Director of the Clinical Trials Office, with a check for \$50,000 for the **Heley Family Breast Cancer Research Fund** in memory of Skip’s beloved wife, Nancy Kammerer Heley. This generous gift will support Dr. Krop’s clinical and translational research program.

Mr. Heley is shown below (left) with Dr. Krop.

Though we know a lot about the biology that often causes kidney cancer, it does not fit neatly into the patterns that we expect for most cancers. These unusual features of its biology drew me to kidney cancer research and treatment and have kept me fascinated over the years.”

— MICHAEL HURWITZ, PHD, MD



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Program
at the Smilow Cancer Hospital

[Read More](#)

Laura Baum, MD, MPH on Colorectal Cancer Awareness Month

“As an oncologist and palliative care provider, I am trained in communication around serious illness and do my best to support patients with colorectal cancer in their understanding of their prognosis and in their decision-making regarding treatment choices.”

Laura Baum, MD, MPH
#colorectalcancerawarenessmonth



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Program
at the Smilow Cancer Hospital

[Read More](#)

Hartford Neighborhood Blood Drive in Honor of Patient on April 3rd



[Read More](#)

Follow us!

facebook



Meet Elena Ratner, MD, gynecologic oncologist at Smilow Cancer Hospital. Dr. Ratner cares for women with ovarian, cervical, endometrial, and uterine cancers. Recently, a patient of Dr. Ratner's shared: "Dr. Ratner is wonderful.....very knowledgeable, compassionate, engaging, friendly..... She is, by far, the best physician I've ever had taking care of me. I trust her completely."



Elena Ratner, MD
Gynecologic Oncologist

"Dr. Ratner is wonderful.....very knowledgeable, compassionate, engaging, friendly..... She is, by far, the best physician I've ever had taking care of me. I trust her completely."

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Division of Yale University School of Medicine
The National Cancer Institute

[Read More](#)



The **Smilow Cancer Hospital Palliative Care Program** had strong representation at the 2022 **Annual Assembly of the American Academy of Hospice and Palliative Medicine** and the **Hospice and Palliative Nurses Association** held virtually last month.

Presentations included:

Medical Repatriation for the Dying Undocumented Patient: Unique Challenges and Unforgettable Lessons

Angela K Chang, MD, Jaya Gupta, DO, and Dmitry Kozhevnikov, DO

Ventricular Assist Devices and Palliative Care: A Case For Continued Palliative Care Involvement

Bryan Terry, MD, Shelli Feder, PhD, FNP, ACHPN, Jennifer Kapo, MD

The Conundrum of High-Flow Oxygen on Hospital Discharge to Home Hospice

Brett Prestia, DO, Joseph Sacco, MD

Exacerbated by Use of Physical Restraints: A Fatal Constellation for a Young Man Living with Disfiguring Hidradenitis

Nora Segar, MD, Mae Williams MDiv, PhD

Managing Acute Decompensation in Life-Limiting Illness (MADLI): A Novel Simulation Curriculum

Dmitry Kozhevnikov, DO, Ambrose Wong, MD, MEd, MHS, Karen Jubanyik, MD, Matthew Ellman, MD, Laura Morrison, MD

The Quality of Telehealth-Delivered Palliative Care During the Initial COVID-19 Pandemic Surge

Ann Soliman, MD, Kathleen Akgün, MD, MS, Jane Coffee, MSW, MSN, APRN, AGPCNP-BC, CHPN, Jennifer Kapo, MD, Laura Morrison, MD, Leslie Blatt, MS, MSN, RN, APRN, Dena Schulman-Green, PhD, Shelli Feder, PhD, FNP, ACHPN

Beyond the Basics: Evidence-based Approaches to Managing Pain in Individuals with Serious Illness and Opioid Use Disorder (OUD) or Non-medical Opioid Use

Jennifer Kapo, MD

Afternoon at the Museum: Connection and Meaning at the Frist Art Museum
Laura Morrison, MD

"I Believe In Miracles," An Interdisciplinary Approach for Integrating Faith and Medicine in Goals of Care Conversations

Leah Tenenbaum, DMin, BCC, Leslie Blatt, MS, MSN, RN, APRN

Parent Priorities in End-of-Life Care for Children with Cancer

Prasanna Ananth, MD, MPH

Assessment in HPM Fellowship Training - Updates from the Assessment Workgroup

Laura Morrison, MD

Bystander Empowerment Workshop: How to Respond to Microaggressions in Clinical Environments

Laura Morrison, MD, Jennifer Kapo, MD

Advancing Interprofessional Hospice and Palliative Care Teamwork with Entrustable Professional Activities

Laura Morrison, MD

Diversity, Equity, and Inclusion

American Association for the Advancement of Science STEMM Equity Achievement (SEA) Change

In a three-part series, SEA Change Director

Dr. Shirley Malcom sat

down with **Aileen Fernandez, PhD**, a postdoctoral fellow in the laboratory of David Rimm, MD, PhD, to discuss their experiences navigating academia as Black women and the future of STEMM.

Watch interview



Advancing Transgender and Gender Diverse Visibility and Inclusion

Join us for a Grand Rounds presentation on “Advancing Transgender and Gender Diverse Visibility and Inclusion and Data Accuracy in Oncology” with Juno Obedin-Maliver, MD, MPH, MAS, (she/her/hers), Assistant Professor, Obstetrics and Gynecology, and Epidemiology & Population Health, Stanford University School of Medicine, and Ash Alpert, MD, MFA, (they/them/theirs), Hematology and Medical Oncology Fellow, Wilmot Cancer Institute, University of Rochester Medical Center, on **Tuesday, March 22 at noon**.

Following their presentation, Drs. Obedin-Maliver and Alpert will host an **online discussion** with all Yale Cancer Center trainees from 1-2pm. Please

join us!

Employee Profile: Claire Healy, MS, and Amanda

Eric was a healthy 56-year-old and had never visited a doctor until his dentist urged him to go. At 57, he had his first colonoscopy where several small precancerous polyps were removed. He has since had another colonoscopy with the same results and will continue with regular monitoring to prevent colon cancer.

Every morning, he and four close friends walk with their dogs in the woods of Westport. The friends, like Eric, are men in their 50s who never had a colonoscopy - until he told them his story and urged them to get screened.

“Now they’re all getting their colonoscopies,” he said. “One of my friends did it the other day and I picked him up at the hospital. I just wish more people would do it.”



[Read More](#)

Thank you to The Melissa Marottoli Hogan Foundation for your incredible support of lung cancer research and patient care at Yale Cancer Center and Smilow Cancer Hospital. Our team had an incredible evening at the annual gala this past weekend, including Dr. Roy Herbst, Dr. Sarah Goldberg, Dr. Anne Chiang, Dr. Scott Gettinger (not pictured), and Alison Marcinek





Claire Healy, MS, and Amanda Ganzak, MS, (left to right) are certified genetic counselors, both with over a decade of experience in cancer genetics. They are Co-Managers for the Smilow Cancer Genetics and Prevention Program and oversee a team of cancer genetic counselors, genetic counselor assistants, and ambulatory care associates that provide expertise and care for patients throughout the Smilow Cancer Hospital Network. Claire and Amanda serve as the outreach coordinators for the Smilow Cancer Hospital Care Centers in Trumbull, Greenwich, Waterford, and at Saint Francis Hospital, to distribute network-wide access to cancer genetics services.

The Smilow Cancer Genetics and Prevention Program is aimed at increasing awareness about hereditary cancer risk and prevention through education and community outreach, as well as making new research advances in the field. The program includes physicians, geneticists, genetic counselors, and other providers who work together to provide a thorough cancer risk assessment, coordination of genetic testing, and development of a personalized cancer screening and prevention plan for people with a hereditary or familial cancer risk. “I value being able to provide comprehensive, multidisciplinary care and increasing patients’ access to genetic testing,” said Amanda, who is also passionate about training and mentoring junior genetic counselors.

Claire and Amanda have a weekly clinic that provides patients with genetic counseling and cancer risk assessment, options for and coordination of genetic testing, and disclosure of genetic test results, including a discussion of the implications of the results for patients and their relatives. In addition to their work in the clinic, Claire and Amanda spearheaded an initiative to reduce barriers for patients to access genetic testing. Together, they also developed and implemented a genetic counseling career ladder aimed at rewarding the hard work and effort of the genetic counseling team to ensure long-term retention of their staff. “I am passionate about the field of genetic counseling and want to ensure that all patients have access to these services



[Read More](#)

Tune in to Yale Cancer Answers, in honor of Colorectal Cancer Awareness Month. Dr. David Madoff explains the role of interventional oncology in the treatment and care of patients with colorectal cancer. Listen on Connecticut Public Radio or download our podcast from iTunes.



[Read More](#)

Discover the different forms of hereditary colorectal cancer, and ask your physician for more information if you have risk factors or concerns.

[Learn more about Lynch Syndrome and Hereditary Polyposis Syndromes.](#)



“counseling and want to ensure that all patients have access to these services despite their geographic location or socioeconomic status,” said Claire.

“Claire and Amanda speak humbly about their accomplishments and careers. Professionally, they are national leaders in cancer genetic counseling and both have distinguished careers. Personally, they are in tune with the global needs, as well as the needs of the patients and staff. Most importantly, because of their dedication, expertise, and perseverance, our program is moving forward. Our organization should be proud to have not only one highly acclaimed genetic counselor manager, but two!” said Jeanette Brooks, Program Manager for the Smilow Cancer Genetics and Prevention Program.

Recent Publications

Hwang Y, Knobf MT.

Sleep Health in Young Women with Breast Cancer: A Narrative Review
Supportive Care in Cancer, Online ahead of print.

[Read More](#)

Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, Chukwueke U, Forst DA, Arrillaga-Romany IC, Dietrich J, Corbin Z, Moliterno J, Baehring J, White M, Lou KW, Larson J, de Sauvage MA, Evancic K, Mora J, Nayyar N, Loeffler J, Oh K, Shih HA, Curry WT, Cahill DP, Barker FG, Gerstner ER, Santagata S.

Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

Nature Communications, 13(1):1325.

[Read More](#)

Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B; ANSELMA collaborative group.

Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA

European Journal of Cancer, Online ahead of print.

[Read More](#)

Detterbeck FC, Nishimura KK, Cilento VJ, Giuliani M, Marino M, Osarogiagbon RU, Rami-Porta R, Rusch VW, Asamura H; IASLC Staging and Prognostic Factors Committee and Advisory Boards.

The IASLC Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the 9th Edition TNM Classification

Journal of Thoracic Oncology, Online ahead of print.

[Read More](#)

Strine MS, Wilen CB.

Tuft Cells are Key Mediators of Interkingdom Interactions at Mucosal Barrier Surfaces

PLoS Pathogens, 18(3):e1010318.

[Read More](#)

Merad M, Blish CA, Sallusto F, Iwasaki A.

The Immunology and Immunopathology of COVID-19

DID YOU KNOW?

5-10% of individuals with colorectal cancer may have a hereditary form?

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated by the National Cancer Institute

[Read More](#)

The dietitians at Smilow Cancer Hospital help our patients make healthy food choices during and after cancer treatment. Check out our video and recipe library for ideas from our nutrition team



[Read More](#)

Yale New Haven Health System celebrated a week of gratitude to recognize and honor our employees who serve with exceptional commitment and compassion. Smilow Cancer Hospital leadership spent time rounding throughout the hospital and at our care centers to visit with staff during the week. Here are a few of the photos they shared!



The Immunology and Immunopathology of COVID-19
Science, 375(6585):1122-1127.

[Read More](#)

Braun DA, Wu CJ.

Tumor-Infiltrating T Cells – A Portrait

New England Journal of Medicine, 386(10):992-994.

[Read More](#)

Knowlton, CA.

Breast Cancer Management during the COVID-19 Pandemic: the Radiation Oncology Perspective

Current Breast Cancer Reports, 14:8–16

[Read More](#)

Dieli-Conwright CM, Harrigan M, Cartmel B, Chagpar A, Bai Y, Li FY, Rimm DL, Pusztai L, Lu L, Sanft T, Irwin ML.

Impact of a Randomized Weight Loss Trial on Breast Tissue Markers in Breast Cancer Survivors

NPJ Breast Cancer, 8(1):29.

[Read More](#)

Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Culine S, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P.

Putative Biomarkers of Clinical Benefit with Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research, Online ahead of print.

[Read More](#)

Hahne J, Wang X, Liu R, Zhong Y, Chen X, Liu X, Khoshnood K, Li X.

Chinese Physicians; Perceptions of Palliative Care Integration for Advanced Cancer Patients: A Qualitative Analysis as a Tertiary Hospital in Changsha, China

BMC Medical Ethics, 23(1):17.

[Read More](#)

Kerekes DM, Khan SA.

Lipid Metabolism in Biliary Tract Cancer: A New Therapeutic Target?

Annals of Surgical Oncology, Online ahead of print.

[Read More](#)

Nguyen RY, Xiao H, Gong X, Arroyo A, Cabral AT, Fischer TT, Flores KM, Zhang X, Robert ME, Ehrlich BE, Mak M.

Cytoskeletal Dynamics Regulates Stromal Invasion Behavior of Distinct Liver Cancer Subtypes

Communications Biology, 5(1):202.

[Read More](#)

Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG.

Diabetes Medications and Risk of Hepatocellular Carcinoma

Hepatology, Online ahead of print



[Read More](#)

We're proudly supporting #DressinBlueDay for our patients and to remind everyone to #GetScreened for colorectal cancer. Everyone should start colon cancer screening at age 45, and have regular follow-up screenings at the recommendation of their physician.



[Read More](#)



New research from @Halene_lab in @MolecularCell reveals mutations in U2AF1 improve the ability of cancer cells

to respond to and survive stress and lead to #MDS and #AML.



A reminder to join the 3rd @ASH_hematology review session tomorrow at noon on #Lymphoma with @SmilowCancer speakers Drs. Francine Foss, Scott Huntington, Shalin Kothari, and

Hepatology, Online ahead of print.

Read More

Leapman MS, Dinan M, Pasha S, Long J, Washington SL 3rd, Ma X, Gross CP.

Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging among Patients with Prostate Cancer

JAMA Oncology, Online ahead of print.

Read More

Miao L, Tang Y, Bonneau AR, Chan SH, Kojima ML, Pownall ME, Vejnar CE, Gao F, Krishnaswamy S, Hendry CE, Giraldez AJ.

The Landscape of Pioneer Factor Activity Reveals the Mechanisms of Chromatin Reprogramming and Genome Activation

Molecular Cell, 82(5):986-1002

Read More

Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K.

Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group

International Journal of Radiation-Oncology-Biology-Physics, 112(4):890-900.

Read More

Ahmed M, Abi-Raad R, Fu L, Holt EH, Adeniran AJ, Cai G.

Performing Calcitonin Immunocytochemistry on an Additional ThinPrep Slide in a Fine-Needle Aspiration Diagnosis of Medullary Thyroid Carcinoma

American Journal of Clinical Pathology, 157(3):426-433.

Read More

Funding and Award Opportunities

ALSF Reach Grant

The purpose of the Reach Grant is to advance ALSF's mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. The award is up to \$250,000 over two years.

Application Deadline: March 22, 2022

Read More

Yale Head and Neck SPORE (YHN-SPORE) Developmental Research Program (DRP)

The Yale Head and Neck SPORE's DRP provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full YHN-SPORE project or to generate preliminary data or evidence of collaboration for other new NIH grant applications.

Letter of Intent Due: Friday March 25, 2022

Read More

Yale Head and Neck SPORE (YHN-SPORE) Career Enhancement

Foss, Scott Huntington, Shaim Kohari, and Tarsheen Sethi



Register to join us for a
#NeuroendocrineTumor #CME

webinar program Thursday, 3/17 at
6:30pmET with @PamelaKunzMD
@MariamAboian and Dr. Sajid Khan.



Join us at Noon today for Yale
Cancer Center Grand Rounds. Dr.

Joseph Ross discusses real-world data in
#clinicaltrials and Dr. Susan Busch shares
insights on insurance mandates for #DBT for
#breastcancer screening



.@LauraVanBaum in honor of
#ColorectalCancerAwarenessMonth-

"The role of #immunotherapy in
#colorectalcancer is impressive and is
improving outcomes for patients with
advanced stage cancer."



Tonight at 7:30pm on @YaleCancer
Answers, in honor of

#ColorectalCancerAwarenessMonth,
@dcmadoff explains the role of interventional
oncology in the treatment and care of
patients with colorectal cancer. Listen live on
@wnpr or download our podcast from
@itunes.



New research from the lab of
@sidichen identifies a way to

"supercharge" tumor-attacking T cells to
advance the effectiveness of CAR-T cell
therapy and potentially expand its use to
solid tumors.



Dr. Michael Hurwitz @Yale_Urology
explains why #kidneycancer is

biologically considered an outlier and the
team approach required to care for patients,
in honor of #WorldKidneyDay and
#KidneyCancerAwarenessMonth



.@PamelaKunzMD shares how she
aims to amplify diverse voices,
advance cancer care equity, and

expand the influence of meeting abstracts as
consultant editor for meeting abstracts of
@JCO_ASCO in the @ASCO Connection.



Today at 3:30PM in Washington,

Yale Head and Neck SPORE (YHN-SPORE) Career Enhancement Program (CEP)

The CEP of the Yale Head and Neck SPORE has been established to educate the next generation of investigators committed to translational research in head and neck cancer. The CEP will provide support to promising junior investigators and/or establish investigators who have not previously conducted head and neck cancer focused research.

Letter of Intent Due: Friday March 25, 2022

[Read More](#)

Hood Child Health Research Awards

The intent of the Award is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist in the transition to other sources of funding. Research projects must have direct relevance to child health.

Application Deadline: March 28, 2022

[Read More](#)

Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24)

The purpose of this FOA is to solicit applications for CUSP2CT U24 Data, Evaluation and Coordinating Center (DECC). The DECC is intended to support CUSP2CT, a program designed to increase referral to NCI-supported clinical trials among underrepresented racial/ethnic minority populations who experience disproportionately higher rates of incidence, morbidity, and mortality for numerous cancer types in comparison to Non-Hispanic Whites.

Application Deadline: March 28, 2022

[Read More](#)

U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers

The purpose of this FOA is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in the United States and investigators in LMICs.

Application Deadline: March 30, 2022

[Read More](#)

SITC FELLOWSHIPS for Early Career Scientists

SITC is dedicated to assisting investigators in advancing the science of immunotherapy and developing new therapeutic approaches. To further this goal, we are offering eight Fellowships and Technology Awards, totaling \$680,000 in funding. These Fellowships and Technology Awards are only available to SITC members.

- **Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship**
- **Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship**
- **AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship**
- **Merck Cancer Immunotherapy Clinical Fellowship**
- **Genentech Women in Cancer Immunotherapy Fellowship**
- **Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy Fellowship**
- **Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship**

DC, Dr. Kim Blenman @YaleCancer will chair a session @MelanomaReAlli Scientific Retreat, the premier gathering of global leaders from across the #melanomaresearch community.



Our @YaleGICancers team joined the UAE Egypt Saudi Arabia

Hepatocellular Cancer Education Collaboration Conference today to share their expertise with colleagues internationally. Thank you @PamelaKunzMD @StaceyMStein @dcmadoff @MehraGolshan for participating!



Thanks to Dr. Alana O'Reilly @alanaeclose @FoxChaseCancer and @Eclose1, for providing her insight on education training and career development, and ways to tackle #healthdisparities in minoritized communities



Congratulations to Faye Rogers, PhD, @RogerslabYale, honored with a @YaleCancer Translational Science Research Prize for her @NatureBiotech paper "Direct targeting of amplified gene loci for proapoptotic anticancer therapy."



Congratulations to @AartiBhatiaMD, recipient of the @YaleCancer Award for Teaching Excellence, in recognition of her dedication to ensuring our trainees acquire the skills needed to develop as clinicians and scientists.

Calendar

Endocrinology Clinical Dilemma

March 18; 12:00 PM

Shanzay Haider

[Learn More](#)

Yale ASH 2021 Highlights

March 18; 12:00 PM

Lymphoma

Scott Huntington, MD, MPH, MSc & Francine Foss, MD

[Learn More](#)

Yale CCFH Rising Stars in Hematology

- **Natera ctDNA Immunotherapy Response Monitoring Fellowship and Technology Award**

Application Deadline: April 5, 2022

Read More

MRA Dermatology Fellowship & Junior Faculty Awards

The aim of this program is to drive greater interest and focus on melanoma in clinical practice and research related to the prevention, detection, diagnosis, and staging of melanoma.

- **MRA Dermatology Fellows Award (1 Year, \$35,000):** Supports dermatology residents, fellows, or post-docs in a dermatology program with research, demonstration, and/or pilot programs focused on melanoma prevention or improving early detection, diagnosis, or prognosis.
- **MRA Dermatology Junior Faculty/Clinical Instructor Award (Up to 2 Years, \$50,000 per year):** Supports new dermatology faculty (clinical instructors or new assistant professors) working in research on melanoma prevention or improving early detection, diagnosis, or prognosis.

Application Deadlines: April 20, 2022

Read More

Yale SPORE in Lung Cancer Career Enhancement Program (CEP)

The CEP of the Yale SPORE in Lung Cancer has been established to educate the next generation of investigators committed to translational research in lung cancer. The CEP will provide support of up to \$50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research.

Letters of Intent Due: April 22, 2022

Read More

Yale SPORE in Lung Cancer Developmental Research Program (DRP) Award

The DRP of the Yale SPORE in Lung Cancer provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full Yale SPORE in Lung Cancer project. The purpose is also to generate preliminary data or evidence of collaboration for new NCI grant applications.

Letters of Due: April 22, 2022

Read More

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care.

This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Application Deadline: April 22, 2022

Read More

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

Yale CCEH Rising Stars in Hematology Series

March 18; 1:00 PM

Transcriptional Control of Regenerative Erythropoiesis

Kyle Hewitt, PhD

Learn More

Yale Cancer Answers

March 20; 7:30 PM

NPR

Colorectal Cancer Awareness Month

Stephen Lattanzi, MD

Learn More

Yale Cancer Center Grand Rounds

March 22; 12:00 PM

Advanced Transgender and Gender Diverse Visibility and Inclusion and Data Accuracy in Oncology

Juno Obedin-Maliver, MD, MPH, MAS, FACOG & Ash B. Alpert, MD, MFA

Learn More

Digestive Diseases Research Seminar

March 22; 5:00 PM

Genome and Immune Engineering for Cell Therapy in Oncology

Sidi Chen, PhD

Learn More

Neuroendocrine Conference

March 23; 4:00 PM

Disorders of Sodium Balance

Shanzay Haider

Learn More

Pharmacology Seminar Series

March 24; 12:30 PM

Cellular and Molecular Determinants of Copper Activation of Protein Kinases in Cancer

Dr. Donita Brady

Learn More

Cancer Genetics and Prevention Seminar

March 24; 2:30 PM

RNF43 and Serrated Polyposis Syndrome and When is a Gastric Carcinoid just a Carcinoid and When is it concerning for MEN1?

Carson Nestler, MS, CGC and Amanda Ganzak, MS, CGC

Center for GI Cancers Weekly Seminar

March 24; 4:15 PM

Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community.

Application Deadline: April 22, 2022

[Read More](#)

Diversity Enhancement Program in Oncology at Yale Cancer Center RFA

The Diversity Enhancement Program in Oncology is an initiative established by the Section of Medical Oncology at YCC. The Program is designed to foster underrepresented in medicine (URiM) trainees' interest in careers in hematology/medical oncology (heme/onc) and to build a pipeline to bring URiM candidates to the YCC Heme/Onc Fellowship Program and YCC-Advanced T32 Training Program for Physician-Scientists.

Application Deadline: April 29, 2022

[Read More](#)

Lung Cancer Research Foundation 2022 RFAs

In keeping with our mission, the LCRF grant program provides funding for research into the prevention, diagnosis, treatment, and cure of lung cancer.

- LCRF Minority Career Development Award (CDA) in Lung Cancer - Application Deadline: May 27, 2022
- LCRF Pilot Grant - Letter of Intent Due: April 30, 2022
- LCRF Research Grant on Early-Detection and Pre-Neoplasia in Lung Cancer - Letter of Intent Due: April 30, 2022
- LCRF Research Grant on Oncogene Driven Lung Cancer - Letter of Intent Due: April 30, 2022

[Read More](#)

Yale Center for Gastrointestinal Cancers (CGIC) Seed Grant Program

This intramural seed grant program is designed to provide pilot funding for team-based basic, translational, clinical, or population health research projects focused on GI cancers.

Application Deadline: May 1, 2022

[Read More](#)

Emergency Awards: RADx-UP - Social, Ethical, and Behavioral

Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01)

The goal of this RADx[®]-UP FOA is to conduct social, ethical, and behavioral implications (SEBI) research to understand and reduce barriers to COVID-19 testing, as well as COVID-19 disparities that arise from barriers to testing among underserved and vulnerable populations. The funding for this initiative is provided from the American Rescue Plan Act of 2021, PL 117-2.

Application Deadline: May 2, 2022

[Read More](#)

Emergency Award: RADx-UP Community-Engaged Research on Rapid

March 24, 4:15 PM

Are Cancers Addicted to Aneuploidy?

Jason Sheltzer, PhD

[Learn More](#)

Campus Conversations

March 25, 3:30 PM

Linear and Parallel Immune Dysfunction and its Implication in Cancer Immunotherapy

Lieping Chen, MD, PhD

[Learn More](#)

Endocrinology Clinical Dilemma

March 25; 12:00 PM

Priyadarshini Balasubramanian

[Learn More](#)

Yale ASH 2021 Highlights

March 25; 12:00 PM

Leukemia

Scott Huntington, MD, MPH, MSc & Francine Foss, MD

Amer Zeidan, MBBS | Nikolai Podoltsev, MD, PhD | Rory Shallis, MD

[Learn More](#)

Yale Cancer Answers

March 27; 7:30 PM

NPR

Molecular Mechanisms of Cancer

Daryl Klein, MD, PhD

[Learn More](#)

VBT Program and CVRC Seminar Series

March 28; 4:00 PM

Endothelial Metabolism

Zoltan Arany, MD, PhD

[Learn More](#)

MB&B Seminar/Paul Sigler Lecture

March 28; 4:00 PM

The Molecular Basis of Histone Code Cross-talk

Cynthia Wolberger, PhD

[Learn More](#)

Yale Cancer Center Grand Rounds

March 29; 12:00 PM

Leveraging Social Media Analysis to Inform Tobacco Prevention and Oncogenic MAP Kinase Signaling Networks

Grace Kong, PhD and Benjamin Turk, PhD

[Learn More](#)

Yale Cell Biology Seminar Series

SARS-CoV-2 Testing among Underserved and Vulnerable Populations (U01)

The goals of this FOA are to implement and rigorously evaluate SARS-CoV-2 rapid testing strategies in communities experiencing COVID-19 health disparities. These two-year Rapid Testing Research Projects will evaluate (1) rapid testing interventions to prevent and control COVID-19 transmission among underserved and vulnerable populations and (2) partnership-driven research to implement and evaluate rapid testing and reduce COVID-19 disparities. The funding for this program is provided from the American Rescue Plan Act of 2021, PL 117-2.

Application Deadline: May 2, 2022

[Read More](#)

ALSF Grant Opportunities

- **NEW! R Accelerated Grant:** This grant provides funding to scientists within their first 10 years of faculty appointment who are focused on research in pediatric oncology that support ALSF's mission to find cures and better treatments for childhood cancers. **Deadline for Submission:** May 12, 2022
- **'A' Award Grant:** ALSF seeks game-changing proposals to substantially advance childhood cancer treatments and cures. The 'A' Award is designed for the early independent career scientist who wants to establish a career in pediatric oncology research and does not have NIH funding. **Deadline for Submission:** May 12, 2022

[Read More](#)

Pew-Stewart Scholars for Cancer Research

The Pew-Stewart Scholars for Cancer Research supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The award provides \$300,000 in flexible support—\$75,000 per year for a four-year period.

Institutional Nomination Due: May 18, 2022

[Read More](#)

TheoryLab Collaborative Grants

The ACS is accepting Idea Abstracts through May 20 for TheoryLab Collaborative (TLC) Grants, which provide pilot grant support for innovative, collaborative research projects utilizing the ACS TheoryLab platform.

Contact: Research.Integration@cancer.org with questions.

Abstract Deadline: May 20, 2022

[Read More](#)

AACR Clinical Oncology Research Fellows Grants

The AACR Clinical Oncology Research (CORE) Training Fellowships

Program is designed to provide an effective industry-academic clinical practicum with a unique training opportunity to develop academic clinicians in drug development.

- AACR Clinical Oncology Research (CORE) Training Fellowships
- AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowships
- AACR-Bayer Clinical Oncology Research Training Fellowships
- AACR-Johnson & Johnson Lung Cancer Initiative Clinical Oncology Research Training Fellowship

Application Deadline: May 31, 2022

[Read More](#)

Epidemiologic Research on Emerging Risk Factors and Liver Cancer

March 29; 1:00 PM

Immune Responses to SARS-CoV-2

Akiko Iwasaki, PhD

[Learn More](#)

Human and Translational Immunology Seminar Series

March 29; 4:00 PM

High Throughput Human T Cell Receptor Sequencing: A New Window into Repertoire Establishment and Alloreactivity

Megan Sykes, MD

[Learn More](#)

Special Seminar

March 30; 11:00 AM

Understanding Normal and Malignant Hematopoiesis

Harry Leighton Grimed, PhD

[Learn More](#)

CPC Research Program Seminar

March 30; 12:00 PM

Liver Cancer Screening: An Ambitious Clinical Trial

Tamar Taddei, MD

[Learn More](#)

Neuroendocrine Conference

March 30; 4:00 PM

Acromegaly Diagnosis and Therapy

Carolina Gonzalez-Lopez, MD

[Learn More](#)

Medical Grand Rounds/2022 Paul B. Beeson Professorship

March 31; 8:30 AM

The Evolution of Treatment for HER2+ Breast Cancer: The Power of Engaging the Right Target

Eric Winer, MD

[Learn More](#)

2021-2022 Immunobiology Seminar Series

March 31; 10:30 AM

From the Thymus to Lymphotoxin to Tertiary Lymphoid Organs

Nancy Ruddle, PhD

[Learn More](#)

Pharmacology Seminar Series

March 31; 12:30 PM

The Importance of Protein Dynamics for Kinase Activation and Inhibitor Design: The

Susceptibility (R01 and R21)

The purpose of these FOAs is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Application Deadline: June 16, 2022

Read More

Lasker Clinical Research Scholars Program (Si2/R00)

This program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

Application Deadline: June 24, 2022

Read More

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)

This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Application Deadline: July 5, 2022

Read More

Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01/R21)

This FOA solicits grant applications proposing to utilize bacteria, archaeobacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics.

Application Deadline: July 5, 2022

Read More

Case of ERK2

Dr. Natalie Ahn

Learn More

Pathology Grand Rounds

March 31; 12:30 PM

Immune based cancer treatment biomarkers

– *The pathologist critical role*

Robert Anders, MD, PhD

Learn More

Cancer Genetics and Prevention Seminar

March 31; 2:30 PM

Extending Cascade Screening Using

Genealogy, DTC Genetics and Social Media

– *The ConnectMyVariant Project*

Brian Shirts, MD, PhD

Learn More

Center for GI Cancers Weekly Seminar

March 31, 4:15 PM

GI ASCO Review

Learn More

Smilow Shares

March 31; 7:00 PM

Understanding Kidney Cancer: New

Treatment Advances & Genetic Implications

Harriet Kluger, MD | Patrick A. Kenney, MD |

David A. Braun, MD, PhD | Michael Hurwitz,

PhD, MD | Clare Healy, CGC

Learn More

Share your news!

Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications